Palatin Technologies (PTN) Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
5/14/2013 7:08:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013.
Help employers find you! Check out all the jobs and post your resume.